Dyne Therapeutics, Inc. Stock-Based Compensation
Dyne Therapeutics, Inc. (DYN) reported Stock-Based Compensation of $14.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $14.98M, a 42.32% increase year-over-year.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.08M, a 0.47% increase year-over-year.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $11.23M, a 7.15% increase year-over-year.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $11.08M, a 26.72% increase year-over-year.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $45.85M, a 0.03% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $45.86M, a 129.64% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $19.97M, a 31.59% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $15.18M, a 13.48% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.98M 10-Q · filed 2026-07-29 | $28.06M 10-Q · filed 2026-07-29 | $39.28M derived: sum of 3 quarters · filed 2026-07-29 | $50.37M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $13.08M 10-Q · filed 2026-05-11 | $24.31M derived: sum of 2 quarters · filed 2026-05-11 | $35.39M derived: sum of 3 quarters · filed 2026-05-11 | $45.91M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $11.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $22.31M derived: sum of 2 quarters · filed 2026-03-02 | $32.83M derived: sum of 3 quarters · filed 2026-07-29 | $45.85M 10-K · filed 2026-03-02 |
| 2025-09-30 | $11.08M 10-Q · filed 2025-11-05 | $21.61M derived: sum of 2 quarters · filed 2026-07-29 | $34.63M 10-Q · filed 2025-11-05 | $45.10M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $10.52M 10-Q · filed 2026-07-29 | $23.54M 10-Q · filed 2026-07-29 | $34.02M derived: sum of 3 quarters · filed 2026-07-29 | $42.77M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $13.02M 10-Q · filed 2026-05-11 | $23.50M derived: sum of 2 quarters · filed 2026-05-11 | $32.24M derived: sum of 3 quarters · filed 2026-05-11 | $38.98M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $19.22M derived: sum of 2 quarters · filed 2026-03-02 | $25.96M derived: sum of 3 quarters · filed 2026-03-02 | $45.86M 10-K · filed 2026-03-02 |
| 2024-09-30 | $8.74M 10-Q · filed 2025-11-05 | $15.48M derived: sum of 2 quarters · filed 2025-11-05 | $35.39M 10-Q · filed 2025-11-05 | $41.12M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $6.74M 10-Q · filed 2025-07-28 | $26.64M 10-Q · filed 2025-07-28 | $32.37M derived: sum of 3 quarters · filed 2026-03-02 | $37.25M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $19.91M 10-Q · filed 2025-05-08 | $25.64M derived: sum of 2 quarters · filed 2026-03-02 | $30.51M derived: sum of 3 quarters · filed 2026-03-02 | $35.26M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $5.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.61M derived: sum of 2 quarters · filed 2026-03-02 | $15.36M derived: sum of 3 quarters · filed 2026-03-02 | $19.97M 10-K · filed 2026-03-02 |
| 2023-09-30 | $4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $9.63M derived: sum of 2 quarters · filed 2024-11-12 | $14.24M 10-Q · filed 2024-11-12 | $18.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $9.37M 10-Q · filed 2024-08-12 | $13.20M derived: sum of 3 quarters · filed 2025-02-27 | $17.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $4.62M 10-Q · filed 2024-05-02 | $8.45M derived: sum of 2 quarters · filed 2025-02-27 | $12.28M derived: sum of 3 quarters · filed 2025-02-27 | $15.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.66M derived: sum of 2 quarters · filed 2025-02-27 | $10.69M derived: sum of 3 quarters · filed 2025-02-27 | $15.18M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $6.86M derived: sum of 2 quarters · filed 2023-10-30 | $11.35M 10-Q · filed 2023-10-30 | $17.36M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.52M 10-Q · filed 2023-08-03 | $13.53M derived: sum of 3 quarters · filed 2023-08-03 | $17.17M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $4.49M 10-Q · filed 2023-05-11 | $10.50M derived: sum of 2 quarters · filed 2023-05-11 | $14.14M derived: sum of 3 quarters · filed 2023-05-11 | $18.38M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $6.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $9.65M derived: sum of 2 quarters · filed 2023-03-02 | $13.89M derived: sum of 3 quarters · filed 2023-03-02 | $17.54M 10-K · filed 2023-03-02 |
| 2021-09-30 | $3.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $7.88M derived: sum of 2 quarters · filed 2022-11-03 | $11.53M 10-Q · filed 2022-11-03 | $15.74M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $7.89M 10-Q · filed 2022-08-04 | $12.11M derived: sum of 3 quarters · filed 2022-08-04 | $14.34M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.65M 10-Q · filed 2022-05-02 | $7.87M derived: sum of 2 quarters · filed 2022-05-02 | $10.10M derived: sum of 3 quarters · filed 2022-05-02 | $10.18M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $6.45M derived: sum of 2 quarters · filed 2022-03-10 | $6.53M derived: sum of 3 quarters · filed 2022-03-10 | $6.59M 10-K · filed 2022-03-10 |
| 2020-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.31M derived: sum of 2 quarters · filed 2021-11-04 | $2.38M 10-Q · filed 2021-11-04 | $2.39M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $141.00K 10-Q · filed 2021-08-05 | $155.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $66.00K 10-Q · filed 2021-05-06 | $80.00K derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $26.00K 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $12.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |